Literature DB >> 19740991

Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection.

Isla Humphreys1, Vicki Fleming, Paolo Fabris, Joe Parker, Bodo Schulenberg, Anthony Brown, Charis Demetriou, Silvana Gaudieri, Katja Pfafferott, Michaela Lucas, Jane Collier, Kuan-Hsiang Gary Huang, Oliver G Pybus, Paul Klenerman, Eleanor Barnes.   

Abstract

Hepatitis C virus subtype 3a is a highly prevalent and globally distributed strain that is often associated with infection via injection drug use. This subtype exhibits particular phenotypic characteristics. In spite of this, detailed genetic analysis of this subtype has rarely been performed. We performed full-length viral sequence analysis in 18 patients with chronic HCV subtype 3a infection and assessed genomic viral variability in comparison to other HCV subtypes. Two novel regions of intragenotypic hypervariability within the envelope protein E2, of HCV genotype 3a, were identified. We named these regions HVR495 and HVR575. They consisted of flanking conserved hydrophobic amino acids and central variable residues. A 5-amino-acid insertion found only in genotype 3a and a putative glycosylation site is contained within HVR575. Evolutionary analysis of E2 showed that positively selected sites within genotype 3a infection were largely restricted to HVR1, HVR495, and HVR575. Further analysis of clonal viral populations within single hosts showed that viral variation within HVR495 and HVR575 were subject to intrahost positive selecting forces. Longitudinal analysis of four patients with acute HCV subtype 3a infection sampled at multiple time points showed that positively selected mutations within HVR495 and HVR575 arose early during primary infection. HVR495 and HVR575 were not present in HCV subtypes 1a, 1b, 2a, or 6a. Some variability that was not subject to positive selection was present in subtype 4a HVR575. Further defining the functional significance of these regions may have important implications for genotype 3a E2 virus-receptor interactions and for vaccine studies that aim to induce cross-reactive anti-E2 antibodies.

Entities:  

Mesh:

Year:  2009        PMID: 19740991      PMCID: PMC2772701          DOI: 10.1128/JVI.00884-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Codon-substitution models for heterogeneous selection pressure at amino acid sites.

Authors:  Z Yang; R Nielsen; N Goldman; A M Pedersen
Journal:  Genetics       Date:  2000-05       Impact factor: 4.562

2.  Genetic characterization of hypervariable region 1 in patients chronically infected with hepatitis C virus genotype 2.

Authors:  X Fan; A M Di Bisceglie
Journal:  J Med Virol       Date:  2001-07       Impact factor: 2.327

3.  Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Authors:  A Fournillier; C Wychowski; D Boucreux; T F Baumert; J C Meunier; D Jacobs; S Muguet; E Depla; G Inchauspé
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

5.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies.

Authors:  P Farci; A Shimoda; A Coiana; G Diaz; G Peddis; J C Melpolder; A Strazzera; D Y Chien; S J Munoz; A Balestrieri; R H Purcell; H J Alter
Journal:  Science       Date:  2000-04-14       Impact factor: 47.728

6.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

7.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

8.  Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2.

Authors:  RosaMaria Roccasecca; Helenia Ansuini; Alessandra Vitelli; Annalisa Meola; Elisa Scarselli; Stefano Acali; Monica Pezzanera; Bruno Bruni Ercole; Jane McKeating; Asutosh Yagnik; Armin Lahm; Anna Tramontano; Riccardo Cortese; Alfredo Nicosia
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

9.  The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection.

Authors:  Eleanor Barnes; Gillian Harcourt; Dave Brown; Michaela Lucas; Rodney Phillips; Geoffrey Dusheiko; Paul Klenerman
Journal:  Hepatology       Date:  2002-09       Impact factor: 17.425

10.  The hepatitis C sequence database in Los Alamos.

Authors:  Carla Kuiken; Peter Hraber; James Thurmond; Karina Yusim
Journal:  Nucleic Acids Res       Date:  2007-11-19       Impact factor: 16.971

View more
  14 in total

1.  Genome-Wide Mutagenesis of Hepatitis C Virus Reveals Ability of Genome To Overcome Detrimental Mutations.

Authors:  Deepak Singh; Shalini Soni; Shaheen Khan; Aditya N Sarangi; Ragothaman M Yennamalli; Rakesh Aggarwal; Naga Suresh Veerapu
Journal:  J Virol       Date:  2020-01-17       Impact factor: 5.103

2.  Interlaboratory Comparison of Six Real-Time PCR Assays for Detection of Bovine Leukemia Virus Proviral DNA.

Authors:  J P Jaworski; A Pluta; M Rola-Łuszczak; S L McGowan; C Finnegan; K Heenemann; H A Carignano; I Alvarez; K Murakami; L Willems; T W Vahlenkamp; K G Trono; B Choudhury; J Kuźmak
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

3.  HCV genotype-3a T cell immunity: specificity, function and impact of therapy.

Authors:  Isla S Humphreys; Annette von Delft; Anthony Brown; Linda Hibbert; Jane D Collier; Graham R Foster; Monira Rahman; Annabel Christian; Paul Klenerman; Eleanor Barnes
Journal:  Gut       Date:  2012-02-15       Impact factor: 23.059

4.  New insight into HCV E1/E2 region of genotype 4a.

Authors:  Nehal Hussein; Abdel-Rahman N Zekri; Mohamed Abouelhoda; Hanaa M Alam El-Din; Ahmed Abdelwahab Ghamry; Mahmoud A Amer; Ghada M Sherif; Abeer A Bahnassy
Journal:  Virol J       Date:  2014-12-30       Impact factor: 4.099

5.  High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease.

Authors:  Ditte L Hedegaard; Damien C Tully; Ian A Rowe; Gary M Reynolds; David J Bean; Ke Hu; Christopher Davis; Annika Wilhelm; Colin B Ogilvie; Karen A Power; Alexander W Tarr; Deirdre Kelly; Todd M Allen; Peter Balfe; Jane A McKeating
Journal:  J Hepatol       Date:  2016-08-13       Impact factor: 25.083

6.  Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.

Authors:  A L McNaughton; V B Sreenu; G Wilkie; R Gunson; K Templeton; E C M Leitch
Journal:  J Viral Hepat       Date:  2018-02-21       Impact factor: 3.728

Review 7.  The past, present and future of neutralizing antibodies for hepatitis C virus.

Authors:  Jonathan K Ball; Alexander W Tarr; Jane A McKeating
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970

8.  ve-SEQ: Robust, unbiased enrichment for streamlined detection and whole-genome sequencing of HCV and other highly diverse pathogens.

Authors:  David Bonsall; M Azim Ansari; Camilla Ip; Amy Trebes; Anthony Brown; Paul Klenerman; David Buck; Paolo Piazza; Eleanor Barnes; Rory Bowden
Journal:  F1000Res       Date:  2015-10-13

9.  The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design.

Authors:  Annette von Delft; Isla S Humphreys; Anthony Brown; Katja Pfafferott; Michaela Lucas; Paul Klenerman; Georg M Lauer; Andrea L Cox; Silvana Gaudieri; Eleanor Barnes
Journal:  Gut       Date:  2015-06-19       Impact factor: 23.059

10.  A modified RNA-Seq approach for whole genome sequencing of RNA viruses from faecal and blood samples.

Authors:  Elizabeth M Batty; T H Nicholas Wong; Amy Trebes; Karène Argoud; Moustafa Attar; David Buck; Camilla L C Ip; Tanya Golubchik; Madeleine Cule; Rory Bowden; Charis Manganis; Paul Klenerman; Eleanor Barnes; A Sarah Walker; David H Wyllie; Daniel J Wilson; Kate E Dingle; Tim E A Peto; Derrick W Crook; Paolo Piazza
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.